Long-term results with growth hormone therapy in idiopathic hypopituitarism

Area of Science:

• Pediatric Endocrinology
• Growth Hormone Therapy
• Child Development

Background:

• Growth hormone (GH) deficiency treatment in children is established but often yields unsatisfactory long-term height outcomes.
• The efficacy of recombinant human GH (rhGH) therapy has been documented for over three decades.
• Factors influencing treatment success, such as timing and duration, require further investigation.

Purpose of the Study:

• To evaluate the long-term efficacy of early-initiated recombinant GH therapy in GH-deficient children.
• To determine the impact of early treatment initiation on achieving target adult height.
• To identify key variables influencing growth response to GH therapy.

Main Methods:

• Retrospective analysis of GH-deficient children treated with daily recombinant GH injections.
• Treatment initiated within the first five years of life.
• Assessment of adult height relative to target height, considering factors like birth weight and pubertal onset.

Main Results:

• Children treated with daily recombinant GH within the first five years of life achieved adult heights close to their target height.
• Early initiation and continuous therapy until adulthood were associated with successful catch-up growth.
• Birth weight significantly influenced growth response, highlighting the role of fetal growth.

Conclusions:

• Early initiation of GH replacement therapy (before age 5) and continuation until adulthood are critical for achieving target height in GH-deficient children.
• Birth weight is a significant predictor of growth response, emphasizing the importance of fetal development.
• Optimizing GH therapy requires consideration of treatment timing, duration, and individual growth factors.